Articles related to Pulmonology

In this randomized trial, standard treatment of rifampin and isoniazid for 24 weeks plus pyrazinamide and ethambutol for the initial 8 weeks was compared with an initial treatment of bedaquiline–linezolid for 8 weeks, extended treatment for persistent clinical disease, monitoring after treatment, and retreatment for relapse. The shorter approach was determined to be non-inferior.

In 60 medical centers, 1,500 patients were randomized to either a restrictive or liberal fluid strategy. The 90-day mortality rate was 14% in the fluid-restrictive group and 14.9% in the liberal group, equating to statistical equivalence between the two approaches.

In this study, more than 12,000 patients 18 years and older with hospitalization for extremity fracture were randomized to LWMH or aspirin. Rates of DVT were 1.7% and 2.5%, respectively. PE, bleeding complications, and other SAEs were similar across groups. Death occurred in 0.73% and 0.78% respectively for LWMH and aspirin.

HER2-Directed ADCs in Gastric Cancer Several antibody-drug conjugates (ADCs) have recently received approval for use in treating a range of solid cancers. This poses difficulties when handling a variety of adverse treatment-related events, some of which can take practitioners into uncharted area. After viewing this CME activity, medical oncologists, pulmonologists, urologists, pathologists, oncology NPs, PAs, oncology nurses, oncology pharmacists, and other HCPs caring for patients with solid tumors should be able to describe the elements of an antibody-drug conjugate (ADC) that may cause adverse events (AEs), identify AEs that result in treatment interruption or discontinuation, and suggest a strategy for managing the key AEs.

This 62-year-old man had a lung transplant 3 years previously for IPF and is on tacrolimus, mycophenolate, and prednisone. Which therapy is most appropriate for their zoster outbreak? IV acyclovir Oral famciclovir Oral valacyclovir Herpes zoster vaccine

Medical oncologists, pulmonologists, pathologists, oncology nurses, pharmacists, and other oncology HCPs who treat patients with lung cancer should be better able to describe ideal evidence-based treatment selection and sequencing recommendations for the use of immuno-oncologic therapy in patients with early-stage NSCLC and evaluate clinical trial data of emerging immunotherapy-based agents in the treatment after completing this three-chapter, 0.50-credit CME activity.